Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bigelovin is a **sesquiterpene lactone** isolated from the plant *Inula helianthus-aquatica*. It functions as a **selective retinoid X receptor α agonist**, demonstrating potent anti-tumor, anti-inflammatory, and anti-angiogenic properties. Bigelovin induces apoptosis and autophagy in various cancer cell lines, including liver and colorectal cancers, by inhibiting the mTOR pathway and generating reactive oxygen species (ROS)[1][3][5][6]. It selectively inhibits the JAK2/STAT3 signaling pathway by inactivating JAK2, reduces NF-κB signaling via IKK-β degradation, upregulates death receptor 5 (DR5), and causes cell cycle G2/M arrest and DNA damage, contributing to its cytotoxic and anti-proliferative effects[2][3][4]. The compound shows efficacy in animal xenograft models and is mainly used in preclinical research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bigelovin.